Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P C Caron

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 1999
A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemiaS E Kossman, D A Scheinberg, J G Jurcic, et al.
Steroids|June 1, 1975
Sex dependence of clearance rates of aldosterone and its metabolites from plasma of intact ratsD J Morris, P C Caron, W C Graham, et al.
The Journal of Experimental Medicine|October 1, 1992
Engineered humanized dimeric forms of IgG are more effective antibodiesP C Caron, W Laird, M S Co, et al.
Cancer Research|December 15, 1992
Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodiesP C Caron, M S Co, M K Bull, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 15, 1992
Chimeric and humanized antibodies with specificity for the CD33 antigenM S Co, N M Avdalovic, P C Caron, et al.
Molecular Immunology|October 1, 1993
Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibodyM S Co, D A Scheinberg, N M Avdalovic, et al.
The Journal of Experimental Medicine|June 1, 1996
The multidrug resistance phenotype confers immunological resistanceJ H Weisburg, M Curcio, P C Caron, et al.
Cancer|February 1, 1994
Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemiaP C Caron, M A Schwartz, M S Co, et al.
Leukemia|February 1, 1995
Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195J G Jurcic, P C Caron, W H Miller, et al.
Blood|April 1, 1994
A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicityP C Caron, J G Jurcic, A M Scott, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 1999
A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemiaS E Kossman, D A Scheinberg, J G Jurcic, et al.
Steroids|June 1, 1975
Sex dependence of clearance rates of aldosterone and its metabolites from plasma of intact ratsD J Morris, P C Caron, W C Graham, et al.
The Journal of Experimental Medicine|October 1, 1992
Engineered humanized dimeric forms of IgG are more effective antibodiesP C Caron, W Laird, M S Co, et al.
Cancer Research|December 15, 1992
Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodiesP C Caron, M S Co, M K Bull, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 15, 1992
Chimeric and humanized antibodies with specificity for the CD33 antigenM S Co, N M Avdalovic, P C Caron, et al.
Molecular Immunology|October 1, 1993
Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibodyM S Co, D A Scheinberg, N M Avdalovic, et al.
The Journal of Experimental Medicine|June 1, 1996
The multidrug resistance phenotype confers immunological resistanceJ H Weisburg, M Curcio, P C Caron, et al.
Cancer|February 1, 1994
Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemiaP C Caron, M A Schwartz, M S Co, et al.
Leukemia|February 1, 1995
Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195J G Jurcic, P C Caron, W H Miller, et al.
Blood|April 1, 1994
A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicityP C Caron, J G Jurcic, A M Scott, et al.
Pageof 3